Kinzalkomb

Hydrochlorothiazide and Telmisartan, the active ingredient in Kinzalkomb, is a combination antihypertensive presented as an oral tablet for systemic use. It is indicated for the treatment of hypertension and for edema associated with high blood pressure in adult patients.

GNH USA supplies Kinzalkomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet clinical demand. Kinzalkomb is manufactured under EU GMP guidelines, ensuring consistent potency and safety for patients across diverse healthcare settings.

Kinzalkomb combines an angiotensin II receptor blocker with a thiazide diuretic to manage conditions related to elevated blood pressure.

Hypertension: reduces systolic and diastolic pressure, lowering overall cardiovascular risk. Edema associated with hypertension: promotes diuresis to decrease fluid overload. Cardiovascular risk reduction in hypertensive patients: helps prevent complications such as stroke and myocardial infarction.

Kinzalkomb may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild hypotension

Serious or Rare Side Effects: - Severe dehydration - Hyperkalemia - Acute renal impairment - Angioedema or severe allergic reaction

When prescribing Kinzalkomb, clinicians should consider several safety measures.

Blood pressure monitoring: check regularly to ensure therapeutic effect and avoid hypotension. Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. Electrolyte balance: monitor potassium and sodium levels, especially when combined with other diuretics. Pregnancy: contraindicated in pregnancy (Category D) due to risk of fetal toxicity. Elderly patients: start at lower dose and monitor for orthostatic hypotension. Store at room temperature: keep in original packaging, protect from moisture and heat.

Kinzalkomb can interact with several drug classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia. - NSAIDs (e.g., ibuprofen): can reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: thiazide component may increase lithium levels, requiring serum monitoring. - ACE inhibitors or other ARBs: additive blood pressure lowering and risk of renal impairment.